Author

M. Noeparast

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:clustering· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1 Approach:genetic perturbation / CRISPR· 1

Frequent Co-Authors

A. Borowek· 1 shared A. C. Joerger· 1 shared A. Nist· 1 shared C. Eggermont· 1 shared D. Drangenstein· 1 shared D.-I. Balourdas· 1 shared E. Pavlakis· 1 shared G. J. Gutierrez· 1 shared

Activity by Year

2022-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Borowek

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Functional diversity of the TP53 mutome revealed by saturating CRISPR mutagenesis

J. Funk, M. Klimovich, E. Pavlakis, M. Neumann, D. Drangenstein, M. Noeparast, P. Hunold, A. Borowek, D.-I. Balourdas, K. Kochan, N. Merle, I. Bullwinkel, M. Wanzel, S. Elmshauser, A. Nist, , T. Stiewe

This study uses CRISPR mutagenesis to analyze the functional impact of TP53 mutations across 9,225 variants, revealing their effects on tumor cell fitness and metastasis.

bioRxiv · Mar 10, 2023Cancer Biology

The EGFR-STYK1-FGF1 axis sustains functional drug tolerance to EGFR inhibitors in EGFR-mutant non-small cell lung cancer

C. Eggermont, P. Giron, M. Noeparast, H. Vandenplas, P. Aza-Blanc, G. J. Gutierrez, J. De Greve

This study identifies STYK1 as a target that enhances the effects of EGFR inhibition in NSCLC cells, suggesting co-targeting EGFR and STYK1 may improve treatment outcomes.

bioRxiv · Apr 26, 2022Cancer Biology